Possible risk of rheumatoid arthritis treated with methotrexate to the central nervous system relapse of diffuse large B-cell lymphoma

Key Points

• CNS relapse risk increases with methotrexate treatment in diffuse large B-cell lymphoma patients, prompting further investigation.
• Relapse observed in patients undergoing rheumatoid arthritis treatment with methotrexate involved in lymphoma management.
• Assessment utilizes clinical data from patients affected by both conditions, using retrospective analysis for insights.
• Findings highlight the need for careful monitoring and possible reevaluation of treatment strategies in this demographic.